Addex Therapeutics (ADXN) Depreciation & Amortization (CF) (2019 - 2025)

Addex Therapeutics has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting -$2.6 billion for Q2 2025.

• Depreciation & Amortization (CF) for Q2 2025 came in at -$2.6 billion, up 96.71% year-over-year; the trailing twelve-month figure through Dec 2025 was -$202.6 million (down 103.49% YoY), and the FY2025 annual result was $10218.3, down 96.56% from the prior year.
• Depreciation & Amortization (CF) came in at -$2.6 billion for Q2 2025 at Addex Therapeutics, down from $2.4 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $272.8 billion in Q3 2024 to a low of -$269.8 billion in Q4 2024.
• The 5-year median for Depreciation & Amortization (CF) is $91999.6 (2021), against an average of $203.9 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 194303126.57% in 2023, while the deepest fall reached 325276525.18% in 2023.
• Addex Therapeutics' Depreciation & Amortization (CF) stood at $89976.8 in 2021, then decreased by 12.73% to $78524.3 in 2022, then sank by 325276525.18% to -$255.4 billion in 2023, then declined by 5.61% to -$269.8 billion in 2024, then jumped by 99.05% to -$2.6 billion in 2025.
• The last three Depreciation & Amortization (CF) figures came in at -$2.6 billion (Q2 2025), $2.4 billion (Q1 2025), and -$269.8 billion (Q4 2024), per Business Quant data.